Drug Details

General Information of the Drug (ID: DR7139)
Name
AMD3100
Synonyms
Plerixafor; 110078-46-1; Mozobil; AMD3100; 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene; Amd 3100; bicyclam JM-2987; plerixafor (amd3100); Plerixafor hydrochloride; AMD-3100; SDZ SID 791; JM3100; JM 3100; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane; JM-3100; UNII-S915P5499N; JKL 169; CHEMBL18442; 1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane; S915P5499N; SID791; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; Mozobil (TN); plerixaforum; Plerixafor [USAN:INN:BAN]; 1,1'-[1,4-phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane); Plerixafor 8HCl; GNA & AMD-3100; HHA & AMD-3100; JM 2987; Plerixafor(AMD3100); 1,4,8,11-Tetraazacyclotetradecane, 1,1'-[1,4-phenylenebis(methylene)]bis-, hydrochloride (1:8); Plerixafor-d4 (deuterated); SCHEMBL19038; GTPL844; cc-304; Plerixafor (JAN/USAN/INN); AOB5591; DTXSID70869520; AMD-3100 (CXCR4); CHEBI:125354; BCPP000104; BCP02337; C28H54N8; EX-A1762; ANW-73610; BDBM50035696; MFCD05662218; NSC754363; NSC761388; s8030; ZINC22443609; 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; AKOS005266706; CCG-269710; CS-0451; DB06809; NSC-754363; NSC-761388; NCGC00165722-01; NCGC00165722-02; NCGC00165722-03; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); AC-26837; AK-41732; AS-42504; HY-10046; AB0009909; FT-0660392; FT-0673966; A25446; D08971; S-7677; AB01566900_01; 078P461; A809618; L000104; Q905835; SR-01000941593; J-503718; SR-01000941593-1; 11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane; BRD-K33240821-367-01-8; Z2196779619; 1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1,1'-(benzene-1,4-diyldimethanediyl)bis(1,4,8,11-tetraazacyclotetradecane); 1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane; 1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA); 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane; 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O); 1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane; 1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane; 11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester
    Click to Show/Hide
Molecular Type
Small molecule
Disease Acute lymphoblastic leukemia [ICD-11: 2B33] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Clearance
The renal clearance of drug is 3.15 L/h
Elimination
70% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 4.4 hours
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7671 micromolar/kg/day
Vd
The volume of distribution (Vd) of drug is 0.3 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C28H54N8
PubChem CID
65015
Canonical SMILES
C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
InChI
1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
InChIKey
YIQPUIGJQJDJOS-UHFFFAOYSA-N
CAS Number
CAS 110078-46-1
ChEBI ID
CHEBI:125354
TTD Drug ID
D0L5RW
DrugBank ID
DB06809
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Triptolide      Tripterygium hypoglaucum     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression AKT1  Molecule Info 
Pathway MAP
Down-regulation Expression BIRC5  Molecule Info 
Pathway MAP
Up-regulation Expression CASP3  Molecule Info 
Pathway MAP
Down-regulation Expression CBY1  Molecule Info 
Pathway MAP
Down-regulation Expression CCND1  Molecule Info 
Pathway MAP
Down-regulation Expression ERK1  Molecule Info 
Pathway MAP
Down-regulation Expression ERK2  Molecule Info 
Pathway MAP
Down-regulation Expression MMP-2  Molecule Info 
Pathway MAP
Down-regulation Expression MMP-9  Molecule Info 
Pathway MAP
Down-regulation Expression MYC  Molecule Info 
Pathway MAP
Up-regulation Expression PARP1  Molecule Info 
Pathway MAP
Down-regulation Expression STAT3  Molecule Info 
Pathway MAP
Down-regulation Expression VEGFA  Molecule Info 
Pathway MAP
                    In-vitro Model MG-63 CVCL_0426 Osteosarcoma Homo sapiens
U2OS CVCL_0042 Osteosarcoma Homo sapiens
SaOS-2 CVCL_0548 Osteosarcoma Homo sapiens
143B CVCL_2270 Osteosarcoma Homo sapiens
HOS-8603 Osteosarcoma Homo sapiens
                    Experimental
                    Result(s)		 AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways.
Target and Pathway
Target(s) C-X-C chemokine receptor 4 (CXCR4)  Molecule Info  [3]
KEGG Pathway Cytokine-cytokine receptor interaction Click to Show/Hide
2 Chemokine signaling pathway
3 Endocytosis
4 Axon guidance
5 Leukocyte transendothelial migration
6 Intestinal immune network for IgA production
7 Pathways in cancer
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
2 IL4 Signaling Pathway
3 Leptin Signaling Pathway
Panther Pathway Axon guidance mediated by Slit/Robo Click to Show/Hide
2 Inflammation mediated by chemokine and cytokine signaling pathway
Pathway Interaction Database S1P3 pathway Click to Show/Hide
2 CXCR4-mediated signaling events
3 Syndecan-4-mediated signaling events
4 HIF-1-alpha transcription factor network
5 Ephrin B reverse signaling
Reactome Binding and entry of HIV virion Click to Show/Hide
2 Chemokine receptors bind chemokines
3 G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like Click to Show/Hide
2 Hematopoietic Stem Cell Differentiation
3 HIV Life Cycle
4 Cardiac Progenitor Differentiation
5 Peptide GPCRs
6 GPCR ligand binding
7 GPCR downstream signaling
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 844).
Reference 2 AMD3100 combined with triptolide inhibit proliferation, invasion and metastasis and induce apoptosis of human U2OS osteosarcoma cells. Biomed Pharmacother. 2017 Feb;86:677-685.
Reference 3 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link